Lv6
1760 积分 2022-10-25 加入
Cleavable linkers in antibody–drug conjugates
1个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
1个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
1个月前
已完结
Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager
1个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
1个月前
已完结
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
2个月前
已完结
Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
2个月前
已完结
Antibody-drug conjugates (ADCs): “Smart Missiles” targeting cancer therapy
2个月前
已完结
The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review
2个月前
已完结
Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients
2个月前
已完结
皖公网安备34019202002308
